Legend Biotech Corp (LEGN) Form 6-K — Sep 14, 2026

$LEGNForm 6-KFiled Sep 14, 2026, 8:00 AM ET0001171843-26-006027Original filing

Legend Biotech Corporation filed a Form 6-K dated September 14, 2026 announcing that an updated clinical pipeline has been made available on its website, with the report signed by Interim Chief Executive Officer Alan Bash. The updated pipeline is anchored by CARVYKTI, the BCMA-directed autologous CAR-T therapy developed with Janssen, Pharmaceutical Companies of Johnson & Johnson. CARTITUDE-5 and CARTITUDE-6 in newly diagnosed multiple myeloma are in patient follow-up, while CARTITUDE-10 remains enrolling.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.